Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Instagram Outage Disrupts Thousands of U.S. Users 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SALT LAKE CITY, Nov. 15, 2017 -- Amedica Corporation (Nasdaq:AMDA), an innovative biomaterial company that develops and manufactures silicon nitride as a platform for biomedical applications, announced today that on November 21, 2017, the company will host a conference call and audio webcast with Dr. Sonny Bal, CEO of Amedica Corporation, to review its third quarter 2017 financial results.
Details related to this call are as follows:
Date: November 21, 2017
Time: 9 AM MST
Conference ID: 13673764
Dial-in: Toll free 877 524 8416
International - +1-412-902-1028
Webcast: Investor section of the company’s website
For those who are not available to listen to the live webcast, a digital replay will be archived on the investor relations section of the Amedica website under Events & Presentations.
About Amedica Corporation
Amedica is focused on the development and application of spinal interbody implants made with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing implants for other biomedical applications, such as wear- and corrosion-resistant hip and knee bearings, and dental implants. The Company’s products are manufactured in its ISO 13485 certified manufacturing facility, and it has a partnership with Kyocera, one of the world’s largest ceramic manufacturers. Amedica’s FDA-cleared and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through its distributor network, and OEM and private label partnerships.
For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.
Forward-Looking Statements
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated within this press release. A discussion of those risks and uncertainties can be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on September 20, 2017, and in Amedica’s other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.
Contacts: Amedica IR 801-839-3502 [email protected]
